Notice of Special Interest (NOSI): Administrative Supplements for Collaborative Activities to Promote Sleep/Circadian Research in ADRD
Notice Number:

Key Dates

Release Date:

March 16, 2021

First Available Due Date:
May 05, 2021
Expiration Date:
May 06, 2021

Related Announcements

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)


Sleep disturbances/circadian disruption is a key clinical issue in dementia patients. Between 40 and 70% of older adults suffer from sleep disturbances or disorders, which are especially prevalent among patients with Alzheimer's Disease and Alzheimer’s Disease Related Dementias (AD/ADRD), i.e., Frontotemporal degeneration (FTD), Lewy Body Disease (LBD), Vascular contributions to Cognitive Impairment and Dementia (VCID), and Mixed Etiology Dementias (MED). The Alzheimer's Disease Research Summits specifically recommended to “invest in understanding the integrative physiology of sleep and elucidating the short- and long-term consequences of disrupted and optimized sleep on brain aging and AD.” Moreover, NIA’s AD/ADRD Research Implementation Milestone 2.F plans to "create new research programs aimed at understanding the integrative physiology of circadian rhythms and sleep and its impact on brain aging and the risk of AD and AD-related dementias at multiple levels (epigenetic, gene expression, proteomic, neuronal, network, systems) to identify new targets and approaches for AD prevention."

The purpose of this one-year administrative supplement program is to facilitate collaborative research to better understand the bi-directional relationship between chronic sleep disturbances/circadian disruption and AD/ADRD pathogenesis. This notice encourages eligible members of the AD/ADRD research community with AD/ADRD awards to apply for supplemental funds to establish new collaborations with sleep/circadian researchers for the advancement of research on the association between sleep disturbances/circadian disruptions with ADRD. This initiative aims to investigate the potential of sleep/circadian-related treatment as a modifier of the development and progression of neurodegeneration.

The proposed studies must be within the scope of the peer-reviewed activities specified within the parent award and collaborators may not have a prior history of collaboration. Active awards with project end dates in FY 2022 or later are eligible. The award may not be in a terminal no-cost extension or going into a no-cost extension in FY 2021.

Only supplement applications to parent awards that have an NS designation for NIH institute are eligible to apply to the NINDS for support under this NOSI.


Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

  • PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

  • Application Due Date(s) – May 5, by 5:00 PM local time of applicant organization.
  • For funding consideration, applicants must include “NOT-NS-21-040” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
  • Requests may be for one year of support only.
  • The Research Strategy section of the application is limited to 6 pages.
  • Application budgets cannot exceed the direct costs of the current year of the parent award (exclusive of Facilities and Administrative costs on sub-contracts). Supplement budget requests may not exceed $250,000 per year in direct costs or 100% of the direct costs of the current year of the parent award (exclusive of Facilities and Administrative costs on sub-contracts), whichever amount is lower. Applications that exceed these limits must receive permission from the project officer and IC Contact prior to submission
  • The application Abstract section should describe the proposed supplement, and the Research Strategy section should include a summary or abstract of the funded parent award or project. The Research Strategy should state the relevance to the parent award and AD/ADRD, and articulate the component(s) and any IC-specific priorities that the supplement is addressing.
  • Applicants are strongly encouraged to notify the program contact at the Institute supporting the parent award that a request has been submitted in response to this FOA in order to facilitate efficient processing of the request.
  • The process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.


Please direct all inquiries to:

Dr. Janet He
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9964

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices